T cell antigen receptor vaccines for active immunotherapy of T cell malignancies

Carmen P. Wong, Craig Okada, John M. Timmerman, Dan W. Denney, Ron Levy

Research output: Contribution to journalArticle

Abstract

We have developed a T cell antigen receptor (TCR) based vaccine for the treatment of T cell malignancies. The murine T cell tumor C6VL was used in this approach. Idiotype TCR vaccines stimulated tumor specific immune responses which specifically protected mice from a subsequent injection of tumor cells. C6VL TCR vaccines made with different adjuvants were compared for their ability to stimulate a humoral and tumor protective immune response. SAF-0, QS-21, IL-12, CD40L, GM-CSF and GM-CSF encapsulated in microspheres were all effective in stimulating a humoral anti-C6VL TCR immune response. Only the immune response stimulated with SAF-1, QS-21, and IL-12 adjuvants protected mice from C6VL tumor challenge. The mechanisms of tumor protection were studied in vivo. The protection stimulated by TCR in SAF-1 required both B cells and CD8+ T cells. TCR vaccines in QS-21, however, do not rely on an intact humoral effector mechanism for their protective effect. Depletion of CD8+ T cells in C6VL TCR QS-21 vaccinated mice negated the protective immune response. Protection mechanism studies using IL-12 as adjuvant is currently underway. To eliminate the need for TCR protein, we have made a recombinant adenovirus encoding for C6VL TCR. Direct inoculation of the virus was not effective in stimulating an anti-C6VL TCR humoral or protective immune response. Currently we are investigating whether dendritic cells infected with C6VL TCR recombinant adenovirus can stimulate a protective immune response.

Original languageEnglish (US)
JournalFASEB Journal
Volume12
Issue number5
StatePublished - Mar 20 1998
Externally publishedYes

Fingerprint

Active Immunotherapy
T-cells
immunotherapy
T-Cell Antigen Receptor
Vaccines
T-lymphocytes
vaccines
antigens
T-Lymphocytes
receptors
Tumors
Neoplasms
immune response
Interleukin-12
Granulocyte-Macrophage Colony-Stimulating Factor
interleukin-12
neoplasms
adjuvants
Adenoviridae
mice

ASJC Scopus subject areas

  • Agricultural and Biological Sciences (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Cell Biology

Cite this

Wong, C. P., Okada, C., Timmerman, J. M., Denney, D. W., & Levy, R. (1998). T cell antigen receptor vaccines for active immunotherapy of T cell malignancies. FASEB Journal, 12(5).

T cell antigen receptor vaccines for active immunotherapy of T cell malignancies. / Wong, Carmen P.; Okada, Craig; Timmerman, John M.; Denney, Dan W.; Levy, Ron.

In: FASEB Journal, Vol. 12, No. 5, 20.03.1998.

Research output: Contribution to journalArticle

Wong, CP, Okada, C, Timmerman, JM, Denney, DW & Levy, R 1998, 'T cell antigen receptor vaccines for active immunotherapy of T cell malignancies', FASEB Journal, vol. 12, no. 5.
Wong, Carmen P. ; Okada, Craig ; Timmerman, John M. ; Denney, Dan W. ; Levy, Ron. / T cell antigen receptor vaccines for active immunotherapy of T cell malignancies. In: FASEB Journal. 1998 ; Vol. 12, No. 5.
@article{0745ecc912694db38e7049656b39feff,
title = "T cell antigen receptor vaccines for active immunotherapy of T cell malignancies",
abstract = "We have developed a T cell antigen receptor (TCR) based vaccine for the treatment of T cell malignancies. The murine T cell tumor C6VL was used in this approach. Idiotype TCR vaccines stimulated tumor specific immune responses which specifically protected mice from a subsequent injection of tumor cells. C6VL TCR vaccines made with different adjuvants were compared for their ability to stimulate a humoral and tumor protective immune response. SAF-0, QS-21, IL-12, CD40L, GM-CSF and GM-CSF encapsulated in microspheres were all effective in stimulating a humoral anti-C6VL TCR immune response. Only the immune response stimulated with SAF-1, QS-21, and IL-12 adjuvants protected mice from C6VL tumor challenge. The mechanisms of tumor protection were studied in vivo. The protection stimulated by TCR in SAF-1 required both B cells and CD8+ T cells. TCR vaccines in QS-21, however, do not rely on an intact humoral effector mechanism for their protective effect. Depletion of CD8+ T cells in C6VL TCR QS-21 vaccinated mice negated the protective immune response. Protection mechanism studies using IL-12 as adjuvant is currently underway. To eliminate the need for TCR protein, we have made a recombinant adenovirus encoding for C6VL TCR. Direct inoculation of the virus was not effective in stimulating an anti-C6VL TCR humoral or protective immune response. Currently we are investigating whether dendritic cells infected with C6VL TCR recombinant adenovirus can stimulate a protective immune response.",
author = "Wong, {Carmen P.} and Craig Okada and Timmerman, {John M.} and Denney, {Dan W.} and Ron Levy",
year = "1998",
month = "3",
day = "20",
language = "English (US)",
volume = "12",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "5",

}

TY - JOUR

T1 - T cell antigen receptor vaccines for active immunotherapy of T cell malignancies

AU - Wong, Carmen P.

AU - Okada, Craig

AU - Timmerman, John M.

AU - Denney, Dan W.

AU - Levy, Ron

PY - 1998/3/20

Y1 - 1998/3/20

N2 - We have developed a T cell antigen receptor (TCR) based vaccine for the treatment of T cell malignancies. The murine T cell tumor C6VL was used in this approach. Idiotype TCR vaccines stimulated tumor specific immune responses which specifically protected mice from a subsequent injection of tumor cells. C6VL TCR vaccines made with different adjuvants were compared for their ability to stimulate a humoral and tumor protective immune response. SAF-0, QS-21, IL-12, CD40L, GM-CSF and GM-CSF encapsulated in microspheres were all effective in stimulating a humoral anti-C6VL TCR immune response. Only the immune response stimulated with SAF-1, QS-21, and IL-12 adjuvants protected mice from C6VL tumor challenge. The mechanisms of tumor protection were studied in vivo. The protection stimulated by TCR in SAF-1 required both B cells and CD8+ T cells. TCR vaccines in QS-21, however, do not rely on an intact humoral effector mechanism for their protective effect. Depletion of CD8+ T cells in C6VL TCR QS-21 vaccinated mice negated the protective immune response. Protection mechanism studies using IL-12 as adjuvant is currently underway. To eliminate the need for TCR protein, we have made a recombinant adenovirus encoding for C6VL TCR. Direct inoculation of the virus was not effective in stimulating an anti-C6VL TCR humoral or protective immune response. Currently we are investigating whether dendritic cells infected with C6VL TCR recombinant adenovirus can stimulate a protective immune response.

AB - We have developed a T cell antigen receptor (TCR) based vaccine for the treatment of T cell malignancies. The murine T cell tumor C6VL was used in this approach. Idiotype TCR vaccines stimulated tumor specific immune responses which specifically protected mice from a subsequent injection of tumor cells. C6VL TCR vaccines made with different adjuvants were compared for their ability to stimulate a humoral and tumor protective immune response. SAF-0, QS-21, IL-12, CD40L, GM-CSF and GM-CSF encapsulated in microspheres were all effective in stimulating a humoral anti-C6VL TCR immune response. Only the immune response stimulated with SAF-1, QS-21, and IL-12 adjuvants protected mice from C6VL tumor challenge. The mechanisms of tumor protection were studied in vivo. The protection stimulated by TCR in SAF-1 required both B cells and CD8+ T cells. TCR vaccines in QS-21, however, do not rely on an intact humoral effector mechanism for their protective effect. Depletion of CD8+ T cells in C6VL TCR QS-21 vaccinated mice negated the protective immune response. Protection mechanism studies using IL-12 as adjuvant is currently underway. To eliminate the need for TCR protein, we have made a recombinant adenovirus encoding for C6VL TCR. Direct inoculation of the virus was not effective in stimulating an anti-C6VL TCR humoral or protective immune response. Currently we are investigating whether dendritic cells infected with C6VL TCR recombinant adenovirus can stimulate a protective immune response.

UR - http://www.scopus.com/inward/record.url?scp=33749303013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749303013&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33749303013

VL - 12

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 5

ER -